Revolution Medicines (RVMD) Total Liabilities (2019 - 2026)

Revolution Medicines' Total Liabilities history runs 8 years deep, the most recent figure standing at $753.8 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 162.47% year-over-year to $753.8 million in Q1 2026; TTM through Mar 2026 was $753.8 million, a 162.47% increase from a year earlier, with the FY2025 full-year figure at $723.2 million, up 146.75% from the prior year.
• Total Liabilities improved to $753.8 million in Q1 2026 per RVMD's latest filing, from $723.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $753.8 million in Q1 2026 and bottomed at $121.0 million in Q1 2023.
• The 5-year median for Total Liabilities is $189.6 million (2024), against an average of $295.8 million.
• Across the five-year window, Total Liabilities declined 8.16% in 2023 and surged 233.01% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $126.7 million in 2022, then jumped by 85.82% to $235.5 million in 2023, then gained by 24.45% to $293.1 million in 2024, then jumped by 146.75% to $723.2 million in 2025, then climbed by 4.23% to $753.8 million in 2026.
• Per Business Quant, the three latest RVMD Total Liabilities figures stand at $753.8 million (Q1 2026), $723.2 million (Q4 2025), and $655.0 million (Q3 2025).